Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, multicenter, long-term extension study to compare the safety and efficacy of TAK-385 (10, 20, and 40 mg) following oral administration for 12 weeks or more in the treatment of endometriosis

Trial Profile

A Phase II, multicenter, long-term extension study to compare the safety and efficacy of TAK-385 (10, 20, and 40 mg) following oral administration for 12 weeks or more in the treatment of endometriosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relugolix (Primary) ; Leuprorelin
  • Indications Endometriosis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Sponsors Takeda
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 24 May 2017 According to a Myovant Sciences media release, results from the study were presented during a poster presentation at the 2017 European Congress of Endocrinology.
    • 24 May 2017 Results published in a Myovant Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top